ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk

ClinicalTrials.gov ID: NCT00412113

Public ClinicalTrials.gov record NCT00412113. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 3, 2026, 10:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 6-Week, Prospective, Randomized, Double-Blind, Double-Dummy Phase IV Clinical Trial Designed to Evaluate the Efficacy of an Aggressive Multi-Risk Factor Management Strategy With Caduet (A3841045) Versus a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensive Subjects With Additional Risk Factors.

Study identification

NCT ID
NCT00412113
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Enrollment
245 participants

Conditions and interventions

Interventions

  • Amlodipine besylate Drug
  • Amlodipine besylate/atorvastatin calcium single pill combination Drug

Drug

Eligibility (public fields only)

Age range
21 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2006
Primary completion
Mar 31, 2008
Completion
Mar 31, 2008
Last update posted
Feb 10, 2021

2007 – 2008

United States locations

U.S. sites
51
U.S. states
23
U.S. cities
47
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35209
Pfizer Investigational Site Birmingham Alabama 35216
Pfizer Investigational Site Birmingham Alabama 35234
Pfizer Investigational Site Mesa Arizona 85206
Pfizer Investigational Site Garden Grove California 92843
Pfizer Investigational Site Mission Viejo California 92692
Pfizer Investigational Site Rancho Santa Margarita California 92688
Pfizer Investigational Site Torrance California 90502
Pfizer Investigational Site Gainesville Florida 32605
Pfizer Investigational Site Kissimmee Florida 34741
Pfizer Investigational Site Melbourne Florida 32935
Pfizer Investigational Site Miami Florida 33176
Pfizer Investigational Site Safety Harbor Florida 34695
Pfizer Investigational Site St. Petersburg Florida 33701
Pfizer Investigational Site Augusta Georgia 30904
Pfizer Investigational Site Tucker Georgia 30084
Pfizer Investigational Site South Bend Indiana 46601
Pfizer Investigational Site Erlanger Kentucky 41018
Pfizer Investigational Site Auburn Maine 04210
Pfizer Investigational Site Warren Michigan 48091
Pfizer Investigational Site Minneapolis Minnesota 55404
Pfizer Investigational Site Chesterfield Missouri 63017
Pfizer Investigational Site Florissant Missouri 63031
Pfizer Investigational Site Omaha Nebraska 68116-2004
Pfizer Investigational Site Henderson Nevada 89014
Pfizer Investigational Site Henderson Nevada 89015
Pfizer Investigational Site Belvidere New Jersey 07823
Pfizer Investigational Site Bridgewater New Jersey 08807
Pfizer Investigational Site Clifton New Jersey 07013
Pfizer Investigational Site Elizabeth New Jersey 07202
Pfizer Investigational Site Hillsborough New Jersey 08844
Pfizer Investigational Site Trenton New Jersey 08618
Pfizer Investigational Site Brooklyn New York 11229
Pfizer Investigational Site Buffalo New York 14209
Pfizer Investigational Site Cincinnati Ohio 45219
Pfizer Investigational Site Cincinnati Ohio 45242
Pfizer Investigational Site Oklahoma City Oklahoma 73103
Pfizer Investigational Site Tulsa Oklahoma 74136
Pfizer Investigational Site Bensalem Pennsylvania 19020
Pfizer Investigational Site Lansdale Pennsylvania 19446
Pfizer Investigational Site Philadelphia Pennsylvania 19146
Pfizer Investigational Site Providence Rhode Island 02904
Pfizer Investigational Site Goose Creek South Carolina 29445
Pfizer Investigational Site Mt. Pleasant South Carolina 29464
Pfizer Investigational Site Bristol Tennessee 37620
Pfizer Investigational Site Kingsport Tennessee 37660
Pfizer Investigational Site Dallas Texas 75235
Pfizer Investigational Site Houston Texas 77030-2324
Pfizer Investigational Site Plano Texas 75093
Pfizer Investigational Site San Antonio Texas 78238
Pfizer Investigational Site Chesapeake Virginia 23320

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00412113, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 10, 2021 · Synced May 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00412113 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →